Baebies
Baebies develops the FINDER multifunctional diagnostic platform powered by proprietary digital microfluidics technology, delivering rapid FDA-cleared molecular, chemistry, and coagulation tests in approximately 15 minutes from 50 microliter samples for hospitals, children's hospitals, and urgent care centers.
- Company typePrivate
- Founded2015
- HeadquartersDurham, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Baebies does
Baebies is a privately held medical diagnostics company headquartered in Durham, North Carolina, with a satellite engineering facility in Hyderabad, India. Founded in 2015 by Richard West and Vamsee Pamula, who previously co-led Advanced Liquid Logic (a Duke spinout sold to Illumina for $96M), Baebies develops rapid near-patient diagnostic platforms powered by proprietary digital microfluidics (DMF) technology. DMF manipulates microliter-sized droplets through electrowetting on a printed circuit board substrate, enabling molecular, immunoassay, chemistry, and coagulation testing on a single multifunctional instrument without tubes, pumps, or valves. The company's primary product, FINDER, is a compact analyzer that accepts disposable cartridges and delivers lab-equivalent results in approximately 15 minutes from 50 microliter samples. SEEKER, a sister platform for newborn screening of lysosomal storage disorders, was divested to a strategic partner after delivering over 22 million tests globally. Baebies holds over 200 global patents and has shipped 25 million+ tests across both platforms.
Baebies' product portfolio includes FDA 510(k)-cleared tests for G6PD deficiency (chemistry) and Flu A/B, RSV, and SARS-CoV-2 (molecular, also CLIA waived), an FDA Breakthrough Device-designated Anti-Factor Xa Test for heparin monitoring (coagulation), and a CE-marked G6PD Test for European markets. Manufacturing operates under ISO 13485:2016 quality systems at the Research Triangle Park facility. Revenue is generated through sale of FINDER instruments and recurring cartridge-based consumables to enterprise healthcare customers including leading children's hospitals, academic medical centers, urgent care networks, and hospital laboratories across the United States, United Kingdom, Europe, and India.
The company's go-to-market relies on enterprise field sales, supplemented by conference presence (notably ADLM), scientific publications, and an Early Access Program for select clinical partners. Baebies has raised approximately $110M+ in cumulative equity and grant funding from investors including Collective Capital Ventures, VentureSouth, Duke Angel Network, Rex Health Ventures, NC Biotechnology Center, and federal agencies including NIH, CDC, RADx, BARDA, and CARB-X. Revenue is not publicly disclosed, and several FINDER modules remain pre-commercial or in Early Access, while the company pursues an active pipeline of additional assays including a sepsis diagnostic funded by CARB-X.
Baebies firmographics
Firmographics- Name
- Baebies
- Legal name
- Baebies, Inc.
- Website
- https://baebies.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Baebies develops the FINDER multifunctional diagnostic platform powered by proprietary digital microfluidics technology, delivering rapid FDA-cleared molecular, chemistry, and coagulation tests in approximately 15 minutes from 50 microliter samples for hospitals, children's hospitals, and urgent care centers.
- Ownership category
- akta.pro rank
Baebies industry classification
Industry- Product category
- In Vitro Diagnostics / Point-of-Care Medical Devices
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
- akta.pro secondary industries
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
Keywords
Where Baebies is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Baebies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Tests/Cartridges: Sale of disposable diagnostic cartridges for the FINDER platform. Multiple test types including G6PD (FDA cleared, CE-marked), Flu A/B SARS-CoV-2 (FDA 510(k) cleared, CLIA waived), and Anti-Factor Xa (FDA Breakthrough Device Designation). Revenue from consumables as customers run tests.
- FINDER Instruments: Sale of FINDER instrument platform - a compact, toaster-sized analyzer that accepts disposable cartridges. Instruments generate ongoing cartridge demand.
- Government R&D Grants: NIH, CDC, RADx, and BARDA funding for development programs including sepsis diagnostics, pediatric coagulation testing, and heparin monitoring. Grants include $2.7M NIH Phase IIB SBIR for heparin monitoring, up to $11.6M CARB-X for sepsis diagnostics, $3M for pediatric coagulation testing.
- SEEKER Newborn Screening Systems: Sale of SEEKER digital microfluidics platform for newborn screening of lysosomal storage disorders. Estimated 10 million tests shipped to date on SEEKER platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | FINDER G6PD Test - FDA-cleared and CE-marked diagnostic test |
| Unit Pricing | Multi-year contract | FINDER Platform - Multifunctional diagnostic analyzer |
| Unit Pricing | Multi-year contract | FINDER Flu A&B/SARS-CoV-2 Test - FDA 510(k) cleared and CLIA waived |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
Baebies product offering
Product offeringCore offering
Baebies develops, manufactures, and sells the FINDER multifunctional diagnostic platform powered by proprietary digital microfluidics technology, enabling rapid near-patient testing across molecular, immunoassay, coagulation, and chemistry modalities on a single compact instrument using disposable cartridges. The company also sells the SEEKER digital microfluidics platform for newborn screening of lysosomal storage disorders, and supports customers with disposable test cartridges, instruments, and clinical collaboration services for hospitals and healthcare systems worldwide.
Product overview
Baebies offers a platform-plus-modules product architecture centered on two core platforms: FINDER and SEEKER. The FINDER multifunctional diagnostic platform supports chemistry, molecular, coagulation, and immunoassay testing through swappable cartridge-based modules including the FDA-cleared FINDER G6PD Test (chemistry), the FDA-cleared and CLIA-waived FINDER Flu A/B/SARS-CoV-2 Test (molecular), and the FDA Breakthrough Device-designated FINDER Anti-Factor Xa Test (coagulation). The SEEKER platform targets newborn screening for lysosomal storage disorders. Both platforms are powered by proprietary digital microfluidics technology.
Differentiator
Problem solved
Functional benefit
Brands
- FINDER: Multifunctional diagnostic platform capable of performing molecular, immunoassay, coagulation, and chemistry tests on the same system using digital microfluidics technology.
- SEEKER
Products and services
- FINDER Multifunctional Diagnostic Platform A multifunctional diagnostic instrument powered by proprietary digital microfluidics technology, capable of performing molecular, immunoassay, coagulation, and chemistry tests on the same system. Compact design no larger than a sheet of paper, delivering results in approximately 15 minutes from 50 microliter samples for near-patient use in hospitals, children's hospitals, academic medical centers, and urgent care settings.
- FINDER G6PD Test A chemistry cartridge test that measures glucose-6-phosphate dehydrogenase enzymatic activity in whole blood using only a 50 microliter sample. FDA 510(k) cleared and CE-marked, delivering results in approximately 17 minutes with lab-equivalent performance (<5% CV). Designed for newborn screening, pre-discharge testing, and pediatric G6PD deficiency detection at hospitals including NYP Columbia, CHOA, and other leading institutions.
- FINDER Flu A/B, RSV, SARS-CoV-2 Test A molecular RT-PCR cartridge test detecting Flu A, Flu B, and SARS-CoV-2 from a single swab in a fully enclosed cartridge with specimen adequacy controls (endogenous RPP30 testing) and over 100 integrity checkpoints. FDA 510(k) cleared and CLIA waived, delivering positive results in as fast as 15 minutes and negatives in about 20 minutes without requiring specialized training.
- FINDER Anti-Factor Xa Test A coagulation cartridge test for heparin monitoring in patients receiving unfractionated or low molecular weight heparin. Uses a novel fluorogenic substrate to overcome chromogenic substrate interference from bilirubin and hemoglobin. Delivers results in under 15 minutes from 50 microliters of whole blood without centrifugation. Developed with NIH Phase IIB SBIR funding in collaboration with Boston Children's Hospital.
- SEEKER Newborn Screening Platform A digital microfluidics platform for newborn screening of lysosomal storage disorders (LSDs) including MPS I, Pompe, Fabry, and Gaucher diseases using dried blood spot samples. Evaluated at Great Ormond Street Hospital (UK) in collaboration with Technopath Distributors Limited.
Quantifiable outcome
- Results in ~15 minutes after sample introduction (vs 1-2 hours for central lab)
- +6 more outcomes
Companies that use Baebies
Customer profileNamed customers12 records
Segments4 records
Ideal customer profiles4 records
Baebies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Baebies partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and key.
- Boston Children's HospitalcoreNIH-funded collaboration continuing development of rapid, low blood volume heparin monitoring test for neonates and pediatric patients. Project creates near-patient testing platform that reduces blood loss and provides timely results for heparin dosing decisions.
- Duke University School of MedicinecoreCollaboration on digital microfluidic sepsis diagnostic that differentiates bacterial infection from non-bacterial illness using host transcription response. Research conducted at Duke University School of Medicine as part of military health applications.
- Cleveland ClinickeyClinical study collaboration examining interference of DOACs (apixaban and rivaroxaban) with anti-Factor Xa test on point-of-care DMF platform. Presented at ADLM 2025 showing the assay remained tolerant to DOAC presence.
- Great Ormond Street Hospital (GOSH) Institute of Child HealthkeyEvaluation of SEEKER digital microfluidics platform for newborn screening of lysosomal storage disorders (MPS I, Pompe, Fabry, Gaucher diseases). Study conducted August 2022 through May 2023 with results presented at BIMDG conference.
- Technopath Distributors LimitedkeyEssential role in success of SEEKER evaluation at GOSH. Distributor supporting digital microfluidics products in UK market.
- Stanford University School of MedicinekeyVinod K. Bhutani, MD, Professor Emeritus of Pediatrics at Stanford was first to evaluate FINDER G6PD assay, assessing device performance and comparing to reference methods. Published evaluation in Seminars in Perinatology 2020.
- NewYork-Presbyterian Hospital - Columbia University Irving Medical CenterkeyClinical collaboration demonstrating G6PD testing using FINDER at 2025 ADLM. Hospital serves high G6PD deficiency prevalence population. Results show hospital testing turnaround of 4.5 hours vs 3.1 days for external lab reference.
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
Baebies competitors and assessment
Company assessmentEmerging players
- Specific Diagnostics: Specific Diagnostics is developing rapid phenotypic AST and species ID from positive blood cultures. Emerging peer with overlapping sepsis/septicemia diagnostic use case that competes with Baebies' CARB-X sepsis platform.
- Mesa Labs: Mesa Labs provides specialty diagnostic and quality-control products, including some POC platforms. Partial overlap with FINDER's chemistry/coagulation testing franchise in decentralized hospital settings, though Mesa's portfolio is broader and more industrial.
Direct peers
- BioFire Diagnostics (bioMérieux): BioFire's FilmArray panels are the syndromic molecular POC standard in hospitals. Comparable to FINDER on rapid, cartridge-based multiplex molecular diagnostics, though BioFire targets higher-complexity lab settings.
- Accelerate Diagnostics: Accelerate Diagnostics offers rapid antimicrobial susceptibility testing directly from positive blood cultures. Comparable to Baebies' sepsis program in addressing time-to-result bottlenecks in bloodstream infection management.
- Nova Biomedical: Nova Biomedical manufactures compact POC blood chemistry analyzers used in hospital and clinical settings. Comparable to FINDER's chemistry and G6PD testing capabilities, particularly for low-volume decentralized use.
- Cepheid (Danaher): Cepheid's GeneXpert is the dominant point-of-care molecular diagnostic platform with a broad FDA-cleared menu across infectious disease. Direct competitor to FINDER in near-patient molecular testing, with much deeper hospital penetration and assay breadth.
- T2 Biosystems: T2 Biosystems develops rapid diagnostics for sepsis and bloodstream infections from whole blood without culture. Highly relevant peer given Baebies' CARB-X-funded sepsis program and overlapping focus on rapid pathogen ID/AST.
- GenMark Diagnostics (Roche): GenMark's ePlex system offers syndromic molecular panels for bloodstream, respiratory, and gastrointestinal infections. Direct comparator to FINDER on rapid, cartridge-based multiplex molecular testing in hospital labs.
- QuidelOrtho: QuidelOrtho's Sofia platform is a leading CLIA-waived rapid immunoassay system for POC settings. Comparable to FINDER on near-patient respiratory and infectious disease testing, though without FINDER's molecular or coagulation capabilities.
Broad incumbents
- Abbott Diagnostics: Abbott's ID NOW and Binax NOW platforms dominate rapid POC molecular and immunoassay testing. Broad incumbent with vast global sales reach, deep menu, and established CLIA-waived respiratory testing that directly competes with FINDER Flu/SARS-CoV-2.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Baebies social profiles
Digital presenceBaebies compliance and trust
Trust signalCompliance6 records
Baebies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Baebies leadership team
Management profileNumber of profiles
Profiles10 records
Baebies funding detail
Funding detailFunding overview
Funding rounds11 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Baebies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Baebies
What does Baebies do?
Baebies develops, manufactures, and sells the FINDER multifunctional diagnostic platform powered by proprietary digital microfluidics technology, enabling rapid near-patient testing across molecular, immunoassay, coagulation, and chemistry modalities on a single compact instrument using disposable cartridges. The company also sells the SEEKER digital microfluidics platform for newborn screening of lysosomal storage disorders, and supports customers with disposable test cartridges, instruments, and clinical collaboration services for hospitals and healthcare systems worldwide.
Is Baebies a public or private company?
Baebies is a private company. It is classified as venture growth investor backed and is currently operating.
When was Baebies founded?
Baebies was founded in 2015. It employs 51 to 100 people.
Where is Baebies based?
Baebies is headquartered in Durham, United States, in the North America region.
How does Baebies make money?
Four revenue lines are on record. Diagnostic Tests/Cartridges are the primary driver. The others are FINDER Instruments, government R&D Grants and SEEKER Newborn Screening Systems.
Who are Baebies's main competitors?
Emerging players on record are Specific Diagnostics and Mesa Labs. Direct peers are BioFire Diagnostics (bioMérieux), Accelerate Diagnostics, Nova Biomedical, Cepheid (Danaher), T2 Biosystems, GenMark Diagnostics (Roche) and QuidelOrtho. Abbott Diagnostics is listed as a broad incumbent.
Does Baebies have an API?
No public API is recorded for Baebies.
What industry is Baebies in?
Baebies's product category is In Vitro Diagnostics / Point-of-Care Medical Devices. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 334516 and its SIC code is 3841.